Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 283.55
-2.45 (-0.86%)
May 19, 2026, 12:14 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 96.82B DKK in the quarter ending March 31, 2026, with 23.99% growth. This brings the company's revenue in the last twelve months to 327.80B, up 8.13% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
327.80B
Revenue Growth
+8.13%
P/S Ratio
3.87
Revenue / Employee
4.83M
Employees
67,900
Market Cap
1.27T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 28.05B |
| H. Lundbeck | 25.52B |
| Genmab | 25.29B |
| Demant | 22.97B |
| GN Store Nord | 16.60B |
| Zealand Pharma | 9.24B |
| ALK-Abelló | 6.56B |
| Embla Medical | 6.21B |
Novo Nordisk News
- 9 hours ago - Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Motley Fool
- 17 hours ago - PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’ - TipRanks
- 18 hours ago - 3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now - The Motley Fool
- 20 hours ago - US Supreme Court rebuffs pharma challenge to Biden-era drug price - Reuters
- 20 hours ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 1 day ago - Novo Nordisk Prepares Wegovy Launch Amidst Growing Weight Loss Drug Competition - GuruFocus
- 1 day ago - Novo Nordisk Eyes Global Push for Wegovy Pill - GuruFocus
- 1 day ago - Novo Nordisk's next obesity battlefront: Winning beyond America - CNBC